Biotech hVIVO expanding clinical trial capacity

The Irish-founded biotech Hvivo is expanding its operations in London to meet growing demand for its human challenge clinical trial services.

Clinical-trial specialist biotech hVIVO has announced the planned expansion of its life sciences hub in Canary Wharf, London.

Due to a growing demand for its services, the company formerly known as Open Orphan, is building a state-of-the-art facility which will include 50 quarantine beds, with potential to expand to 70 beds, and virology and immunology labs.

There will also be an outpatient unit to facilitate phase two and three clinical trials.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO Canary Wharf facilities

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    hVIVO Careers – Fueling Scientific Research

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    Hvivo raises full year sales and earnings guidance

    The Dublin-headquartered pharmaceutical services company said it expects to generate full year sales of £55m and earnings margins of 19 per cent Hvivo, the Irish pharmaceutical services company founded by businessman Cathal Friel, has increased its sales and

    hVIVO plc

    hVIVO reports surge in half year revenues as HCTs rise

    hVIVO, formerly Open Orphan, has today reported a jump in revenues and earnings for the six months to the end of June and said its outlook for the full year was “extremely positive”. It raised its 2023 revenue

    hVIVO plc

    hVIVO plc Upgraded Full Year Revenue and EBITDA Guidance

    hVIVO plc (Euronext & LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June 2023. Financial highlights ·    First half revenue growth of

    hVIVO plc

    A day in the life of a clinical trial volunteer

    What does a day look like as a clinical trial volunteer? FluCamp is a leading clinical research organization focused on studying and developing treatments for respiratory illnesses. We conduct clinical trials and recruit volunteers to contribute to medical

    hVIVO plc

    Hvivo to move to larger “state-of-the-art” facility in London

    The Dublin-headquartered pharmaceutical services company said the expanded facility would allow it to capitalise on its growing order book Hvivo, the Dublin-listed pharmaceutical services company founded by businessman Cathal Friel, has announced plans to move to a new,

    hVIVO plc

    Hvivo plans larger London facility to meet demand

    Pharmaceutical services firm Hvivo, formerly Open Orphan, has announced plans to open a larger facility in response to the company’s growing order book. Hvivo focuses on advancing research in infectious and respiratory diseases. The new facility will be

    hVIVO plc

    hVIVO plans for a new consolidated facility in Canary Wharf, London

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its plans for a new consolidated facility at the fast-growing life sciences hub in Canary Wharf, London. The expansion,

    hVIVO plc

    hVIVO to release interim results on Tuesday 12 September 2023

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its interim results for the six months ended 30 June 2023 on Tuesday 12 September

    hVIVO plc

    How our Drug Development Plan can help you get funding

    An academic spin-off biotech with only a handful of people on board was preparing for their new biological entity for clinical development. For the drug product itself, they needed to a CMC process and conduct necessary nonclinical studies.

    hVIVO plc

    VP of Clinical Operations on hVIVO’s new Facility

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    Developing an Influenza B Human Challenge Model

    Dr. Andrew Catchpole, Chief Scientific Officer discusses hVIVO’s bespoke human challenge model development services focusing on our most recent Flu B model. He highlights the various stages of this contract & the fundamental steps hVIVO takes to ensure

    No more posts to show